Details for Patent: 9,011,905

Which drugs does patent 9,011,905 protect, and when does it expire?

Patent 9,011,905 protects QSYMIA and is included in one NDA.

This patent has forty patent family members in seventeen countries.

Summary for Patent: 9,011,905

Patent landscape, scope, and claims:

Title:	Low dose topiramate/phentermine composition and methods of use thereof
Abstract:	A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
Inventor(s):	Najarian; Thomas (Los Osos, CA), Tam; Peter Y. (Redwood City, CA), Wilson; Leland F. (Menlo Park, CA)
Assignee:	Vivus, Inc. (Mountain View, CA)
Application Number:	14/495,246
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,011,905
Patent Claim Types: see list of patent claims	Formulation; Dosage form; Composition;

Drugs Protected by US Patent 9,011,905

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-001	Jul 17, 2012	AB	RX	Yes	No	9,011,905		Y
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-002	Jul 17, 2012	AB	RX	Yes	No	9,011,905		Y
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-003	Jul 17, 2012	AB	RX	Yes	No	9,011,905		Y
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-004	Jul 17, 2012	AB	RX	Yes	Yes	9,011,905		Y

International Family Members for US Patent 9,011,905

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2317997		CA 2021 00049	Denmark
European Patent Office	2317997		CR 2021 00049	Denmark
European Patent Office	2317997		2190050-1	Sweden
Australia	2009257572
Australia	2009257573
Brazil	PI0914985